Analysis of an additional immunotherapy cohort, the MSK lung cancer cohort, corroborated our findings, demonstrating that mutations in KEAP1 or STK11 were linked to unfavorable outcomes, as evidenced by significantly poorer OS (Figure 2e). Here, STK11 is linked to lung carcinoma.